India · Delayed Price · Currency is INR Caplin Point Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profits saw robust multi-year growth, with strong cash reserves and zero debt. Expansion in injectables, U.S. and LATAM markets, and disciplined CapEx position the business for sustained double-digit growth and high margins in coming years.
-
Q3 FY26 saw double-digit revenue and profit growth, margin expansion, and strong cash flow. US and Latin America drive future growth, with new product launches, regulatory approvals, and major CapEx investments supporting long-term expansion.
-
Revenue and profit margins grew strongly in H1 FY26, with PAT up 21.6% and EBITDA margin expanding. Expansion in the U.S., Mexico, and Latin America, along with robust cash reserves, positions the company for continued growth and potential acquisitions.
-
Q1 FY2026 delivered 11.7% revenue growth and 20.7% PAT growth, driven by strong Latin America and U.S. performance, robust margins, and a focus on asset-light models. Management projects continued double-digit growth, with new product launches and CapEx supporting future expansion.
Fiscal Year 2025
-
Revenue grew 15% to INR 2,034 crore and PAT rose 17% to INR 541 crore, with record margins and strong liquidity. U.S. and Latin America expansions, new product launches, and disciplined capital allocation underpin a focus on sustainable, high-quality growth.
-
Nine-month FY25 revenue and profits surpassed FY23 full-year levels, driven by strong U.S. and LATAM growth, robust margins, and a strategic shift to own-label launches in the U.S. Expansion into Mexico and Chile, new product approvals, and internal funding support a positive multi-year outlook.
-
Q2 FY25 revenue grew 17.8% year-over-year, with strong performance in core, sterile, and new business segments. Expansion in Latin America and the U.S. continues, with a shift toward B2C and asset-light models, while maintaining robust margins and cash flows.
-
Q1 FY25 saw 17% revenue and 20% PAT growth, with gross margin rising to 59.6% and strong cash reserves. U.S. and Latin America drove performance, Caplin Steriles' contribution increased, and major CapEx is planned for injectables and API facilities.